{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:07:20Z","timestamp":1791493640994,"version":"4.3.4"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Nephroblastoma (Wilms tumor, WT) is an extremely rare and aggressive malignancy in adults with nonspecific clinical and imaging features. There is no standard therapy for patients with progressive disease despite surgery and chemotherapy. Here, we report a unique case of a 27-year-old male patient with recurrent metastatic nephroblastoma who developed resistance to PD-1 inhibitor and targeted therapy. Radiofrequency ablation (RFA) was performed on the largest porta pulmonic lesion. Notably, 3 months post-ablation, a non-ablated pleural lesion exhibited a partial response. Follow-up confirmed PR of the pleural lesion and total disappearance of pleura-irritative symptoms. This case demonstrates a potential abscopal effect induced by RFA, in which local treatment of one tumor site coincided with systemic regression of distant, untreated lesions and reversal of prior PD-1 inhibitor resistance.<\/jats:p>","DOI":"10.3389\/fonc.2025.1640409","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T04:17:59Z","timestamp":1759897079000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: Abscopal response and reversal of PD-1 resistance in a patient with nephroblastoma following radiofrequency ablation"],"prefix":"10.3389","volume":"15","author":[{"given":"Mengyang","family":"Ju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0037","article-title":"Wilms tumor, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Balis","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-3-319-30046-7_5","article-title":"Adult wilms\u2019 Tumor","volume-title":"Rare genitourinary tumors","author":"Madan","year":"2016"},{"key":"B3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12894-024-01508-6","article-title":"First incidence of extrarenal wilms tumor within the spinal canal in the adult population: a novel case report and literature review","volume":"24","author":"Alijani","year":"2024","journal-title":"BMC Urol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"102799","DOI":"10.1016\/j.eucr.2024.102799","article-title":"Pediatric regimens in the treatment of adult-onset, metastatic Wilms tumor: A case report","volume":"56","author":"Howell","year":"2024","journal-title":"Urol Case Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.15586\/jkcvhl.v10i3.281","article-title":"Recent improvements in adult wilms tumor diagnosis and management: review of literature","volume":"10","author":"Sakthivel","year":"2023","journal-title":"J Kidney Cancer VHL"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-018-0617-1","article-title":"Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial","volume":"11","author":"Guo","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2023-0127-OA","article-title":"Wilms tumor: an unexpected diagnosis in adult patients","volume":"148","author":"Chan","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1507011","article-title":"Blastemal predominant WT1 negative Wilms tumour of the young adult: a unique case report and review of the literature","volume":"12","author":"\u0160karda","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1397","article-title":"Immune checkpoint inhibitors in Wilms\u2019 tumor and Neuroblastoma: What now","volume":"4","author":"Valind","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12943-023-01759-1","article-title":"Exosome-derived circCCAR1 promotes CD8\u2009+\u2009T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma","volume":"22","author":"Hu","year":"2023","journal-title":"Mol Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.248","article-title":"Targeting SLC7A11\/xCT improves radiofrequency ablation efficacy of HCC by dendritic cells mediated anti-tumor immune response","volume":"3","author":"Jin","year":"2024","journal-title":"Imeta"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.746","article-title":"Radiofrequency ablation: mechanisms and clinical applications","volume":"5","author":"Wu","year":"2024","journal-title":"MedComm (2020)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1055\/a-2015-5535","article-title":"Treatment of thyroid nodules with radiofrequency ablation","volume":"44","author":"Kaltoft","year":"2023","journal-title":"Ultraschall der Med - Eur J Ultrasound"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01532","article-title":"Radiofrequency ablation versus stereotactic body radiotherapy for recurrent small hepatocellular carcinoma: A randomized, open-label, controlled trial","volume":"43","author":"Xi","year":"2025","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000003242","article-title":"Assessing the impact of radiofrequency ablation on hilar cholangiocarcinoma: a systematic review and meta-analysis","author":"Zhou","year":"2025","journal-title":"Int J Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202502375","article-title":"A synergistic 3D-printed collar transforms radiofrequency ablation into potent thermal immunotherapy for lung cancer","author":"Chen","year":"2025","journal-title":"Adv Mater"},{"key":"B18","doi-asserted-by":"crossref","first-page":"105508","DOI":"10.1016\/j.esmoop.2025.105508","article-title":"Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC)","volume":"10","author":"Seligmann","year":"2025","journal-title":"ESMO Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1352","article-title":"PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor","volume":"22","author":"Shi","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ph16121672","article-title":"Inducing the abscopal effect in liver cancer treatment: the impact of microwave ablation power levels and PD-1 antibody therapy","volume":"16","author":"Liao","year":"2023","journal-title":"Pharm (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s00262-024-03718-1","article-title":"Enhanced abscopal anti-tumor response via a triple combination of thermal ablation, IL-21, and PD-1 inhibition therapy","volume":"73","author":"Wu","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092206","article-title":"How compatible are immune checkpoint inhibitors and thermal ablation for liver metastases","volume":"14","author":"Minami","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1640409\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T04:18:00Z","timestamp":1759897080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1640409\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":22,"alternative-id":["10.3389\/fonc.2025.1640409"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1640409","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"article-number":"1640409"}}